<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) represents a serious health care problem in the Czech Republic, introducing a need for a prospective modelling of the incidence and prevalence rates </plain></SENT>
<SENT sid="1" pm="."><plain>The prevalence of patients requiring anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy is also of great importance, as it is directly associated with planning of health care resources </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This work proposes a population-based model for the estimation of stage-specific prevalence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients who will require active anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy in a given year </plain></SENT>
<SENT sid="3" pm="."><plain>Its applicability is documented on records of the Czech National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy in the Czech Republic in 2015 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Several scenarios are adopted to cover the plausible development of the incidence and survival rates, and the probability of an anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy initiation </plain></SENT>
<SENT sid="5" pm="."><plain>Based on the scenarios, the model predicts an increase in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prevalence from 13% to 30% in comparison with the situation in 2008 </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, the model predicts that 10,074 to 11,440 CRC patients will be indicated for anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy in the Czech Republic in 2015 </plain></SENT>
<SENT sid="7" pm="."><plain>Considering <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="C0741884" disease_type="Neoplastic Process" abbrv="">terminal cancer</z:e> recurrence and <z:hpo ids='HP_0000001'>all</z:hpo> patients primarily diagnosed in stage IV, it is predicted that 3,485 to 4,469 CRC patients will be treated for the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> in 2015, which accounts for more than one third (34-40%) of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients treated this year </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: A new model for the estimation of the number of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients requiring active anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> therapy is proposed in this paper </plain></SENT>
<SENT sid="9" pm="."><plain>The model respects the clinical stage as the primary stratification factor and utilizes solely the population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry data </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, no specific hospital data records are needed in the proposed approach </plain></SENT>
<SENT sid="11" pm="."><plain>Regarding the short-term prediction of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> burden in the Czech Republic, the model confirms a continuous increase in the burden that must be accounted for in the future planning of health care in the Czech Republic </plain></SENT>
</text></document>